 Print page |
 Email page |
- The ATA Unveils New Data to FDA
On Bioequivalence of Levothyroxine (October 4, 2006)
- ATA submits letter to Department
of Health and Human Services requesting that thyrotropin alfa
be included in the list of drugs available through the Medicare
competitive acquisition program (CAP) (September 1, 2005)
- Letter
to FDA regarding ATA’s concern of FDA instructing thyroxine
manufacturers to delete the warning that patients
have retitration of their thyroxine dose when they are switched
between brands. (August 3, 2005)
- FDA
Workshop Follow-up Letter (June 30, 2005)
- Joint Public Meeting on
Equivalence of Levothyroxine Sodium Products - Agenda (May
23, 2005 PDF File, 27KB)
- FDA workshop on bioequivalence
co-sponsored by the ATA, The Endocrine Society, and AACE (April
20, 2005)
- AACE, TES, and ATA Joint Position
Statement on the Use and Interchangeability of Thyroxine Products (December 8, 2004)
- Thyroid
Experts Warn of Clinically Important Differences in Potency of
FDA-Approved Levothyroxine Products
(August 11, 2004)
- Thyroid
Experts Speak Out Against the FDA’s Decision to Approve
Generic Levothyroxine Preparations
(June 28, 2004)
- ATA, TES, and AACE express disappointment
and concern for the health of millions of thyroid patients after
FDA announces decision to approve generic substitutes for levothyroxine
product (June 24, 2004)
- ATA and Endocrine Sister Societies
urge FDA to consider expert opinion and the health of millions
of thyroid patients (May 26, 2004)
- ATA, AACE and TES respond to FDA
postponement of workshop (March 19, 2004)
- FDA Bioequivalence Workshop Plans
continue with ATA, Endocrine Society and AACE leaders (December
30, 2003)
- Draft
Levothyroxine Workshop Agenda (PDF File)
- FDA invites ATA, TES & AACE
to Plan Workshop on Thyroxine Bioequivalence (November, 5,
2003)
- ATA Continues Dialog With FDA on
Levothyroxine Dose Precision and Bioequivalence Standards (October 1, 2003)
- ATA
asks the FDA to ensure safe and effective levothyroxine preparations (April 4, 2003)
- ICD-9 Codes Recommended to Medicare by the
ATA
- ATA Members Appointed to a National Academy of Sciences Committee to Assess Health Implications of Perchlorate Ingestion
